Intellia Therapeutics Inc (FRA:38I)
€ 11.365 -0.31 (-2.66%) Market Cap: 1.17 Bil Enterprise Value: 635.81 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 56/100

Intellia Therapeutics Inc Call To Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Transcript

Feb 28, 2022 / 09:30PM GMT
Release Date Price: €90.38 (+10.33%)
Operator

Good afternoon, and welcome to Intellia Therapeutics investor event to discuss the interim clinical results from the Phase I study of NTLA-2001. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.

I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, operator, and good afternoon, everyone. Welcome to Intellia's presentation of additional interim data from the Phase I clinical trial of NTLA-2001 for the treatment of ATTR amyloidosis.

Earlier this afternoon, we issued a press release detailing the results from our ongoing study. This release and the accompanying slide presentation can be found on the Investors and Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live, and a replay of the event will be archived on Intellia's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot